Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 1, 2009, Pages 27-36

  Joyce, Vilija R ^a   Barnett, Paul G ^a   Bayoumi, Ahmed M ^b,c   Griffin, Susan C ^d   Kyriakides, Tassos C ^e   Yu, Wei ^a   Sundaram, Vandana ^a,f   Holodniy, Mark ^a   Brown, Sheldon T ^g   Cameron, William ^h   Youle, Mike ⁱ   Sculpher, Mark ^d   Anis, Aslam H ^j   Owens, Douglas K ^a,f  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f STANFORD UNIVERSITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

AIDS; Health status indicators; Highly active; Highly active antiretroviral therapy; HIV; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HEALTH UTILITIES INDEX MARK 3; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOME STUDY HIV HEALTH SURVEY; MENTAL HEALTH; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOCIAL ASPECT; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; VIRUS LOAD; VISUAL ANALOG SCALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SOCIOECONOMICS;

ADULT; ANTI-HIV AGENTS; CANADA; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 64249151889     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818ce6f3     Document Type: Article

References (44)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337:725-733.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279: 450-454.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
4. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
5. Honiden S, Sundaram V, Nease RF, et al. The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res. 2006;15:69-82.
6. Jelsma J, Ferguson G. The determinants of self-reported health-related quality of life in a culturally and socially diverse South African community. Bull World Health Organ. 2005;82:206-212.
7. Mrus JM, Leonard AC, Yi MS, et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med. 2006;21 (Suppl 5):S39-S47.
8. Mrus JM, Sherman KE, Leonard AC, et al. Health values of patients coinfected with HIV/Hepatitis C: are two viruses worse than one? Med Care. 2006;44:158-166.
9. Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005;14:971-980.
10. Tillmann HL, Kaiser T, Claes C, et al. Differential influence of different hepatitis viruses on quality of life in HIV positive patients. Eur J Med Res. 2006; 11:381-385.
11. Jelsma J, Maclean E, Hughes J, et al. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care. 2005;17:579-588.
12. Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials. 2003;24:481-500.
13. Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-493.
14. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care. 1998;36:126-137.
15. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven; 1996.
16. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43: 203-220.
17. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
18. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001;21:329-334.
19. Richardson J. Cost utility analysis: what should be measured? Soc Sci Med. 1994;39:7-21.
20. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40:113-128.
21. Sumner W, Nease R, Littenberg B. U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care. 1991:701-705.
22. Sanders GD, Owens DK, Padian N, et al. A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. Proc Annu Symp Comput Appl Med Care. 1994:20-24.
23. Tsevat J. What do utilities measure? Med Care. 2000;38:II160-II164.
24. Wu AW, Jacobson KL, Frick KD, et al. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002; 11:273-282.
25. Lenert LA, Feddersen M, Sturley A, et al. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med. 2002; 113:229-232.
26. Revicki DA, Moyle G, Stellbrink HJ, et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquina-vir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS. 1999;13:851-858.
27. Huang IC, Wu AW, Finnern HW, et al. Health-related quality of life and tolerability in treatment-experienced HIV-1 -infected patients on tipranavir versus comparator regimens. Antivir Ther. 2008;13:15-25.
28. Wu AW. MOS-HIV Health Survey: Users Manual: Johns Hopkins University; Baltimore, MD, 1999.
29. Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001;32:E47-E52.
30. Miners AH, Sabin CA, Mocroft A, et al. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials. 2001;2:484-492.
31. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131:194-198.
32. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care. 1996;34:44-57.
33. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res. 1999; 8:471-480.
34. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombol study. AIDS. 2000; 14:1171-1180.
35. Coplan PM, Cook JR, Carides GW, et al. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis. 2004;39:426-433.
36. Johnson ES, Sullivan SD, Mozaffari E, et al. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. Pharmacoeconomics. 1996; 10: 623-629.
37. Kempen JH, Martin BK, Wu AW, et al. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology. 2003; 110:987-995.
38. Oliva J, Roa C, del Llano J. Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. Pharmacoeconomics. 2003;21: 1113-1121.
39. Tillmann HL, Manns MP, Claes C, et al. GB virus C infection and quality of life in HIV-positive patients. AIDS Care. 2004; 16:736-743.
40. Zinkernagel C, Taffe P, Rickenbach M, et al. Importance of mental health assessment in HIV-infected outpatients. J Acquir Immune Defic Syndr. 2001;28:240-249.
41. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
42. Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26: 391-400.
43. Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22: 27-38.
44. Marra CA, Marion SA, Guh DP, et al. Not all "quality-adjusted life years" are equal. J Clin Epidemiol. 2007;60:616-624.